Table 2.

Characteristics of clinical trials conducted among migraine patients using vitamins B₆, B₉, and B₁₂.

Study location	Control		Placebo	Duration of administration	Outcomes	P value	Reference
	Dose	Sample size	Dose   Sample size
Australia	Vitapop tablet containing B6 (25 mg), B9 (2 mg) & B12 (400 μg) once daily	37	Compared with baseline	6 months	Migraine disability	0.010
					Frequency of headache	0.040	[36]
					Headache pain severity	0.002
Australia	Vitapop tablet containing B6 (25 mg), B9 (2 mg) & B12 (400 μg) once daily	103	Compared with baseline	6 months	Migraine disability	0.022
					Frequency of headache	0.460	[45]
					Headache pain severity	0.017